Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Haeckel
M Baud

Showing results (221-230 of 224) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 224 results.
Revue Des Maladies Respiratoires|November 10, 2021
[Rapid outpatient diagnostic pathways for lung cancer: Evaluation after one year]F Millet, M Wislez, V Fallet, et al.
Blood Cancer Journal|September 20, 2014
Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusionA Maurizot, J-P Beressi, B Manéglier, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferonJ P Zarski, M Maynard-Muet, S Chousterman, et al.
Journal Des Maladies Vasculaires|February 19, 2010
[Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients]P Mismetti, J-M Baud, F Becker, et al.
Pageof 23

Showing results (221-230 of 224) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 224 results.
Revue Des Maladies Respiratoires|November 10, 2021
[Rapid outpatient diagnostic pathways for lung cancer: Evaluation after one year]F Millet, M Wislez, V Fallet, et al.
Blood Cancer Journal|September 20, 2014
Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusionA Maurizot, J-P Beressi, B Manéglier, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferonJ P Zarski, M Maynard-Muet, S Chousterman, et al.
Journal Des Maladies Vasculaires|February 19, 2010
[Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients]P Mismetti, J-M Baud, F Becker, et al.
Pageof 23